SCHEMBL244236

SCHEMBL244236

COC(=O)c1ccc(Br)o1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 7/20 0.68
HTT P42858 3/20 0.68
TSHR P16473 3/20 0.56
GLA P06280 1/20 0.56
ALDH1A1 P00352 7/20 0.55
HSD17B10 Q99714 2/20 0.55
KDM4E B2RXH2 2/20 0.55
MAPK10 P53779 1/20 0.55
CYP1A2 P05177 2/20 0.55
CYP2C19 P33261 2/20 0.55
MEN1 O00255 1/20 0.55
NPC1 O15118 3/20 0.54
RAB9A P51151 3/20 0.54
LMNA P02545 2/20 0.54
SMN1; SMN2 Q16637 2/20 0.54
MAPT P10636 1/20 0.54
PKM P14618 1/20 0.54
HPGD P15428 2/20 0.53
IDO1 P14902 1/20 0.53
L3MBTL1 Q9Y468 2/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL69791 0.84 HTT (0.69) KMT2AHTTTSHRALDH1A1KDM4E
SCHEMBL21981938 0.82 HTT (0.67) KMT2AHTTTSHRALDH1A1KDM4E
SCHEMBL29390370 0.82 KMT2A (0.50) KMT2AHTTTSHRGLAALDH1A1
Ethylene SCHEMBL22615238 0.80 HTT (0.64) KMT2AHTTTSHRALDH1A1KDM4E
SCHEMBL4675517 0.79 HTT (0.58) KMT2AHTTTSHRALDH1A1KDM4E
SCHEMBL1179297 0.79 KMT2A (0.54) KMT2AHTTTSHRGLAALDH1A1
SCHEMBL362159 0.79 TSHR (0.63) KMT2ATSHRGLAALDH1A1HSD17B10
SCHEMBL13753395 0.79 ALDH1A1 (0.67) KMT2AHTTTSHRALDH1A1KDM4E
SCHEMBL8121320 0.79 ALDH1A1 (0.58) KMT2AHTTTSHRALDH1A1HSD17B10
SCHEMBL28024073 0.79 KMT2A (0.54) KMT2AHTTTSHRGLAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 633 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119410225-A High-wear-resistance seamless steel pipe material and preparation method thereof 江苏玖骏钢管科技有限公司 2025-02-11 CN claimed
CN-112939829-B Synthetic method of aryl trifluoromethyl thioether 武汉药明康德新药开发有限公司 2023-02-21 CN claimed
CN-114044905-B Preparation method of end-group functionalized polydimethylsiloxane 复旦大学 2023-01-06 CN claimed
CN-114044905-A Preparation method of end group functionalized polydimethylsiloxane 复旦大学 2022-02-15 CN claimed
CN-112939829-A Synthetic method of aryl trifluoromethyl thioether 武汉药明康德新药开发有限公司 2021-06-11 CN claimed
CN-109734689-A A method of furandicarboxylic acid is prepared using cuprous halide salt 河南中医药大学 2019-05-10 CN claimed
CN-102675297-B Preparation method of Lapatinib Ren Fu Pharmaceutical Group stock company (CN) 2014-10-15 CN claimed
CN-102675297-A Preparation method of Lapatinib WUHAN HUMANWELL HEALTHCARE GROUP CO LTD 2012-09-19 CN claimed
US-20260076962-A1 LANTHIONINE SYNTHETASE C-LIKE 2-BASED THERAPEUTICS NIMMUNE BIOPHARMA, INC. (US) 2026-03-19 US disclosed
US-20260062426-A1 CYCLIN DEPENDENT KINASE DEGRADERS AND METHODS OF USE THEREOF DIFFERENTIATED THERAPEUTICS INC (US) 2026-03-05 US disclosed
US-12522618-B2 Copper complexes for treatment of neurodegenerative disorders ALS THERAPY DEVELOPMENT INSTITUTE (US) 2026-01-13 US disclosed
EP-4673449-A1 CYCLIN DEPENDENT KINASE DEGRADERS AND METHODS OF USE THEREOF Differentiated Therapeutics Inc (US) 2026-01-07 EP disclosed
US-12502388-B2 Lanthionine synthetase C-like 2-based therapeutics NIMMUNE BIOPHARMA, INC. (US) 2025-12-23 US disclosed
US-20250361244-A1 BICYCLIC HETEROCYCLYL DERIVATIVES AS IRAK4 INHIBITORS AURIGENE ONCOLOGY LTD (IN) 2025-11-27 US disclosed
US-4990518-A Platelet activating factor G. D. SEARLE & CO. (US) 1991-02-05 US disclosed
US-4983619-A Leukotriene antagonists LILLY INDUSTRIES LIMITED (GB) 1991-01-08 US disclosed
EP-0322164-A2 Ethanolamine derivatives GLAXO GROUP LIMITED (GB) 1989-06-28 EP disclosed
CN-87105515-A Derivatives of phenylbutenamide compounds and preparation method thereof 1988-03-23 CN disclosed
EP-0259972-A2 Heterocyclic propene amide derivatives, processes for their preparation and their use as pharmaceuticals LILLY INDUSTRIES LIMITED (GB) 1988-03-16 EP disclosed
US-4282246-A Antidiabetic furancarboxylic and thiphenecarboxylic acids PFIZER INC. (US) 1981-08-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12502388-B2 Lanthionine synthetase C-like 2-based therapeutics LANCL2, CBS, LCP2 KMT2A 2759/4885HTT 3949/4885TSHR 1860/4885
US-20260062426-A1 CYCLIN DEPENDENT KINASE DEGRADERS AND METHODS OF USE THEREOF CCNA1, CCNE1, CCNA2 KMT2A 777/4885HTT 3503/4885TSHR 358/4885
US-20260076962-A1 LANTHIONINE SYNTHETASE C-LIKE 2-BASED THERAPEUTICS SCLY, CLCN2, CBS KMT2A 2706/4885HTT 4272/4885TSHR 869/4885
US-20250361244-A1 BICYCLIC HETEROCYCLYL DERIVATIVES AS IRAK4 INHIBITORS IRAK4, IRAK3, IRAK1 KMT2A 481/4885HTT 4240/4885TSHR 4307/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.